La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting

2 pages

Amsterdam Molecular Therapeutics (AMT) Holding N.V.

Ajouté le : 15 juillet 2012
Lecture(s) : 15
Signaler un abus
Amsterdam Molecular Therapeutics (AMT)
Holding N.V. (in liquidation) Announces
Publication of its Accounts for 2011 and Notice
of Annual General Meeting
PR Newswire
AMSTERDAM, July 13, 2012
AMSTERDAM
,
July 13, 2012
/PRNewswire/ --
Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext:
AMT) published its Annual Report and Accounts for the year ended
December
31, 2011
and announced that it will host its Annual General Meeting at its
headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost,
the
Netherlands
) at 14.00 hrs on
September 12, 2012
. Shareholders of the
dissolved company are invited to attend.
For further details, agenda and voting information, visit:
http://www.amtbiopharma.com/investors/shareholder-information
About Amsterdam Molecular Therapeutics (AMT)
Holding N.V. (in liquidation)
On
March 30, 2012
, an extraordinary general meeting of shareholders
approved a major corporate restructuring and financing transaction involving
the disposal of AMT's entire business and operations to uniQure B.V. and the
subsequent dissolution, liquidation and delisting of AMT. On
April 5
, the disposal
completed and AMT's dissolution as resolved by the extraordinary general
meeting of shareholders became effective, with Mr. Jörn Aldag and Mr. Piers
Morgan being appointed as the liquidators charged with the liquidation of the
company's dissolved property. On
April 26, 2012
, the liquidators made an
advance distribution - consisting of depositary receipts for ordinary class B in
uniQure B.V. - to AMT's shareholders. There will not be any further (final)
distributions made to AMT shareholders.
AMT and the AMT shares will continue to exist until the liquidation is finalised,
which is expected to occur before the end of 2012. AMT and its shares ceasing
to exist upon the ending of the liquidation shall effectively also result in the
delisting of AMT, to the extent the delisting cannot be achieved at an earlier
date in consultation with Euronext Amsterdam and subject to such conditions as
Euronext Amsterdam may propose.
Further information on AMT, can be found on AMT's website
http://www.amtbiopharma.com.
Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues," "estimates,"
"intends," "projects," "goals," "targets" and other words of similar meaning are
intended to identify such forward-looking statements. Such statements are
based on current expectations only. Undue reliance should not be placed on
these statements because, by their nature, they are subject to known and
unknown risks and can be affected by factors that are beyond the control of
AMT (in liquidation). Actual results could differ materially from current
expectations due to a number of factors and uncertainties. AMT (in liquidation)
expressly disclaims any intent or obligation to update any forward-looking
statements herein except as required by law.
PRN NLD
Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin